• 1. Evolving better nanoparticles: Genetic algorithms for optimising cluster geometries
  Dalton Trans., 2003, 4193-4207
• 2. Evolution of hierarchical porous structures in supramolecular guest–host hydrogels?
  Christopher B. Rodell,Christopher B. Highley,Minna H. Chen,Neville N. Dusaj,Chao Wang,Lin Han,Jason A. Burdick Soft Matter, 2016,12, 7839-7847
• 3. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
• 4. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 5. Excellent humidity sensor based on ultrathin HKUST-1 nanosheets?
  Qiaoe Wang,Meiling Lian,Xiaowen Zhu,Xu Chen RSC Adv., 2021,11, 192-197

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Oxazinanes Morpholines Morpholine carboxylic acids and derivatives

Comprehensive Guide to tert-butyl 2,2-dimethylmorpholine-4-carboxylate (CAS No. 1467262-20-9)

tert-butyl 2,2-dimethylmorpholine-4-carboxylate (CAS No. 1467262-20-9) is a specialized organic compound widely used in pharmaceutical synthesis and fine chemical applications. This morpholine derivative features a tert-butyl ester group and two methyl substituents, making it a valuable building block for drug discovery and material science. With the increasing demand for heterocyclic compounds in medicinal chemistry, this molecule has gained significant attention from researchers and manufacturers alike.

The molecular structure of tert-butyl 2,2-dimethylmorpholine-4-carboxylate combines the rigidity of a morpholine ring with the steric bulk of tert-butyl group, creating unique chemical properties. Recent studies highlight its potential as an intermediate in the synthesis of bioactive molecules, particularly in developing central nervous system (CNS) drugs. The compound's stability under various conditions makes it particularly useful for multi-step organic synthesis, a feature highly valued in modern pharmaceutical R&D.

From a commercial perspective, 1467262-20-9 has seen growing market demand due to its applications in small molecule drug development. Pharmaceutical companies frequently search for reliable suppliers of this high-purity chemical intermediate, especially those offering GMP-grade materials for clinical trial applications. The compound's synthetic versatility allows for modifications at multiple positions, enabling medicinal chemists to create diverse molecular libraries for high-throughput screening programs.

Quality control is paramount when working with tert-butyl 2,2-dimethylmorpholine-4-carboxylate. Reputable manufacturers typically provide comprehensive analytical data including HPLC purity, NMR spectra, and mass spectrometry results. Recent advances in continuous flow chemistry have improved the production efficiency of such N-heterocyclic compounds, addressing common questions about scalability and cost-effectiveness in industrial applications.

The storage and handling of CAS 1467262-20-9 require standard laboratory precautions. While not classified as hazardous under normal conditions, proper chemical storage protocols should be followed to maintain product integrity. Many researchers inquire about the compound's solubility profile—it demonstrates good solubility in common organic solvents like dichloromethane, THF, and ethyl acetate, but limited solubility in water.

In the context of green chemistry initiatives, synthetic routes to 2,2-dimethylmorpholine derivatives have evolved to minimize environmental impact. Current research explores catalytic methods and atom-economical processes for producing such intermediates, responding to growing industry concerns about sustainable pharmaceutical manufacturing. These developments align with frequent search queries about eco-friendly synthesis of drug intermediates.

The patent landscape surrounding tert-butyl 2,2-dimethylmorpholine-4-carboxylate reveals its importance in proprietary drug formulations. Intellectual property searches often focus on its use in protease inhibitors and kinase modulators, reflecting the compound's relevance to cutting-edge therapeutic areas. Analytical chemists frequently investigate its chromatographic behavior using advanced techniques like UPLC-MS for quality assessment.

From a regulatory standpoint, 1467262-20-9 is not currently listed on any controlled substance schedules, making it accessible for legitimate research purposes. However, responsible sourcing remains crucial, as evidenced by increasing searches for certified chemical suppliers and analytical documentation. The compound's structural analogs continue to be explored for various therapeutic applications, maintaining strong interest in this chemical class.

Future perspectives for tert-butyl 2,2-dimethylmorpholine-4-carboxylate include potential applications in bioconjugation chemistry and prodrug development. Its hydrolytic stability and steric properties make it attractive for designing targeted drug delivery systems. As the pharmaceutical industry increasingly focuses on precision medicine, such specialized intermediates will likely see expanded utilization in structure-activity relationship studies.

For researchers considering tert-butyl 2,2-dimethylmorpholine-4-carboxylate synthesis, recent literature describes optimized procedures using microwave-assisted techniques and phase-transfer catalysis. These methods address common questions about reaction yield improvement and byproduct minimization. The compound's growing importance is reflected in its inclusion in several commercial screening libraries and fragment-based drug discovery platforms.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)